HUTCHMED (China) Ltd
H7T1
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,796
Stocks News & Analysis
stocks
ASX listed bank overvalued despite strong earnings
Profit beats drive shares higher for Australia’s largest asset manager.
stocks
After earnings, is Amazon a buy, a sell, or fairly valued?
After the launch of Amazon Supply Chain Services, here’s what we think of the stock.
stocks
ASX retail share expected to recover despite choppy conditions
Weakening consumer demand a temporary headwind for ASX retailer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,942.40 | 14.50 | 0.16% |
| CAC 40 | 8,056.38 | 56.19 | -0.69% |
| DAX 40 | 24,350.28 | 11.65 | 0.05% |
| Dow JONES (US) | 49,656.67 | 47.51 | 0.10% |
| FTSE 100 | 10,269.43 | 36.36 | 0.36% |
| HKSE | 26,406.84 | 13.13 | 0.05% |
| NASDAQ | 26,263.11 | 16.04 | 0.06% |
| Nikkei 225 | 62,417.88 | 295.77 | -0.47% |
| NZX 50 Index | 13,210.48 | 35.35 | 0.27% |
| S&P 500 | 7,408.53 | 9.60 | 0.13% |
| S&P/ASX 200 | 8,701.80 | 11.50 | 0.13% |
| SSE Composite Index | 4,225.02 | 45.07 | 1.08% |